Related Experiment Video
Updated: Feb 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications
Luca Bonanni1,2, Ada Cutolo3,4, Nicola Ferri5
1Department of Medicine, Ospedale dell'Angelo, Venice, Italy. luca.bonanni@aulss3.veneto.it.
The 2025 ESC/EAS Dyslipidaemia Focused Update refines lipid-lowering strategies, emphasizing faster treatment intensification and new therapies for cardiovascular risk reduction. It promotes personalized, sustained low-density lipoprotein cholesterol (LDL-C) management for better outcomes.
Area of Science:
- Cardiology
- Lipidology
- Preventive Medicine
Background:
- The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines provide a framework for dyslipidaemia management.
- Emerging evidence necessitates a focused update to incorporate new findings and refine clinical practice.
Purpose of the Study:
- To revise and update the 2019 ESC/EAS Dyslipidaemia guidelines with recent evidence.
- To provide actionable recommendations for optimizing lipid-lowering therapies before the next comprehensive guideline revision.
Main Methods:
- Integration of new clinical trial data and real-world evidence.
- Re-evaluation of risk stratification tools, including SCORE2/SCORE2-OP, lipoprotein(a) [Lp(a)], and coronary artery calcium (CAC) scoring.
- Assessment of novel lipid-lowering agents and treatment intensification strategies.
Main Results:
- Low-density lipoprotein cholesterol (LDL-C) treatment targets remain consistent.
- Emphasis on accelerated therapeutic intensification and expanded use of combination therapies.
- Introduction of new evidence supporting bempedoic acid, inclisiran, and evinacumab for specific patient groups.
- Reinforcement of proactive, early-intensification strategies in acute coronary syndrome (ACS) settings.
Conclusions:
- The update enhances the operational framework for LDL-C management.
- Promotes earlier, personalized, and sustained lipid lowering to minimize cumulative atherosclerotic exposure.
- Offers refined guidance for managing dyslipidaemia, particularly in high-risk individuals and those with statin intolerance.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures

